Acute myeloid leukaemia (AML) is a deadly blood cancer that creates an uncontrollable buildup of white blood cells. Because of the bad outcomes of this disease, experts all over the world have been looking for novel strategies to treat AML while still allowing for normal blood development.
According to a new, phase 2 clinical trial led by Dana-Farber Cancer Institute doctors, a three-medicine combination that drove chronic lymphocytic leukaemia (CLL) patients into profound remissions in a clinical study is very beneficial in patients with high-risk variants of the disease.